This information is intended for US healthcare professionals.

Ongoing research is exploring cancer's disguise:

COULD BLOCKING CD47 ENHANCE ANTITUMOR IMMUNITY?1,2

Research suggests that blocking CD47 may reactivate macrophage phagocytosis and potentially bolster the innate immune response1

Select the labels on the diagram below to explore the potential impact of diminished CD47 signaling

A graphic of macrophage phagocytosis.
1 2 3 4
A graphic of macrophage phagocytosis.
1macrophage
1
When CD47 “don’t eat me” signaling is blocked, research suggests macrophages may regain the ability to eliminate malignant cells when guided by “eat me” signals.1
2antigens and debris
2
During the typical process of phagocytosis, macrophages “eat” malignant cells and break them down into antigens and debris.2,4
3malignant cell
3
Without protection from CD47 “don’t eat me” signaling, malignant cells may be phagocytosed by macrophages.1
4“eat me” signals
4
The decrease of “don’t eat me” signals with the activation of “eat me” signals may lead to improved macrophage activity.3
Image adapted from references.1,4

Ongoing research suggests that blocking CD47 may restore phagocytosis to normal functioning. Normal functioning of phagocytosis may subsequently lead to T-cell activation in the adaptive immune system5

A graphic of a macrophage presenting antigens to a T-cell. A graphic of a macrophage presenting antigens to a T-cell. Image adapted from references.2,4,5

Could the activation and upregulation of “eat me” signals have the potential to enhance clearance of malignant cells?

Could enhancing innate and, subsequently, adaptive immunity result in more robust antitumor immune responses in myeloid malignancies?

Ongoing research is revealing the role of CD47.

Sign up for more information

CD47, cluster of differentiation 47.

References: 1. Chao MP, Takimoto CH, Feng DD, et al. Front Oncol. 2020;9:1380. doi:10.3389/fonc.2019.01380 2. van Duijn A, Van der Burg SH, Scheeren FA. J Immunother Cancer. 2022;10(7):e004589. doi:10.1136/jitc-2022-004589 3. Yang H, Xun Y, You H. Biomark Res. 2023;11(1):15. doi:10.1186/s40364-023-00456-x 4. Feng M, Jiang W, Kim BYS, et al. Nat Rev Cancer. 2019;19(10):568-586. doi:10.1038/s41568-019-0183-z 5. Jia X, Yan B, Tian X, et al. Int J Biol Sci. 2021;17(13):3281-3287. doi:10.7150/ijbs.60782 6. Liu X, Kwon H, Li Z, et al. J Hematol Oncol. 2017;10(1):12. doi:10.1186/s13045-016-0381-z

Gilead Oncology logo in white text. Gilead Oncology logo in white text.

GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc.
© 2023 Gilead Sciences, Inc. All rights reserved. US-UNBP-2023 08/23